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Maintenance of genome integrity is critical for proper cell growth. This occurs through accurate
DNA replication and repair of DNA lesions. A key factor involved in both DNA replication and the
DNA damage response is the heterotrimeric single-stranded DNA (ssDNA) binding complex
Replication Protein A (RPA). Although the RPA complex appears to be structurally conserved
throughout eukaryotes, the primary amino acid sequence of each subunit can vary considerably.
Examination of sequence differences along with the functional interchangeability of orthologous
RPA subunits or regions could provide insight into important regions and their functions. This
might also allow for study in simpler systems. We determined that substitution of yeast
Replication Factor A (RFA) with human RPA does not support yeast cell viability. Exchange of a
single yeast RFA subunit with the corresponding human RPA subunit does not function due to
lack of inter-species subunit interactions. Substitution of yeast Rfa2 with domains/regions of
human Rpa2 important for Rpa2 function (i.e., the N-terminus and the loop 3–4 region) supports
viability in yeast cells, and hybrid proteins containing human Rpa2 N-terminal phospho-
mutations result in similar DNA damage phenotypes to analogous yeast Rfa2 N-terminal
phospho-mutants. Finally, the human Rpa2 N-terminus (NT) fused to yeast Rfa2 is phosphory-
lated in a manner similar to human Rpa2 in human cells, indicating that conserved kinases
recognize the human domain in yeast. The implication is that budding yeast represents a
potential model system for studying not only human Rpa2 N-terminal phosphorylation, but also
phosphorylation of Rpa2 N-termini from other eukaryotic organisms.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY
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The accumulation of mutations in the cellular genome can lead to
cellular disease. To prevent mutation, prokaryotic and eukaryotic
cells have systems to recognize and repair DNA lesions before
they become mutations. Replication Protein A (RPA) is the
eukaryotic form of single-stranded binding (SSB) protein essential
for proper DNA duplication and maintenance. In human cells, the
32-kilodalton (kDa) subunit of RPA, called Rpa2, is hyper-
phosphorylated on its N-terminus in response to DNA damage.
It is important to examine Rpa2 phosphorylation in other
eukaryotic organisms to fully understand how phosphorylation
contributes to Rpa2 function. When expressed in a single-celled
eukaryotic organism (budding yeast), the human Rpa2
N-terminus is recognized and phosphorylated similarly to that
observed in human cells. We propose that budding yeast could be
a powerful tool to study phosphorylation of Rpa2 N-termini from
other eukaryotes where technical limitations to studying phos-
phorylation currently exist.Introduction
Understanding the basic mechanisms by which the integrity of
genomic DNA is maintained is central to understanding how
mutations are prevented. There are numerous ways in which DNA
integrity can be compromised, including errors in DNA replica-
tion, exposure to environmental stresses, and progression
through natural physiological processes. Cells have numerous
mechanisms to prevent DNA lesions and to deal with DNA lesions
that do arise. Despite this, some DNA lesions can remain
unrepaired or be repaired incorrectly, resulting in permanent
changes (mutations) in the DNA.
Many DNA processes in the cell are carefully coordinated in an
effort to maximize efﬁciency and minimize errors in the cellular
genome. Processes such as DNA replication and DNA repair/
recombination result in the formation of a DNA intermediate
(single-stranded DNA; ssDNA) that ultimately must be processed
to an intact double-stranded DNA (dsDNA) form. At the center of
these DNA processing events is the heterotrimeric protein com-
plex Replication Protein A (RPA). The major biochemical activity of
RPA is to bind ssDNA with high afﬁnity and low sequence
speciﬁcity through multiple oligonucleotide/oligosaccharide
-binding (OB)-fold domains (i.e., DNA binding domains; DBDs)
located within the three subunits [1–3]. The largest subunit, Rpa1
(Rpa70; 70 kDa), is the major contributor to high-afﬁnity ssDNA
binding [4,5], while the smallest subunit, Rpa3 (Rpa14; 14 kDa),
appears to be important for heterotrimeric complex formation [6].
The medium subunit, Rpa2 (Rpa32; 32 kDa) is thought to not only
contribute to ssDNA binding [7,8], but also to regulate function of
the RPA complex, especially in response to DNA damage, through
multiple post-translational modiﬁcations (PTMs) [9–14].
The major emphasis of studies of RPA post-translational mod-
iﬁcation have focused on phosphorylation of the human Rpa2
N-terminus (NT) on multiple serine/threonine (S/T) residues
located within the ﬁrst 40 amino acids (aa) [15,16]. Human
Rpa2 is phosphorylated both in vitro and in vivo on speciﬁc
residues by multiple kinases during DNA replication and in
response to speciﬁc DNA damaging agents. While some of thesetargets are consensus sequences (S/TQ) for phosphatidylinositol–3
(PI3)-related kinases (ATM and ATR) involved in checkpoint
regulation, others are phosphorylation targets of cyclin-
dependent kinase (CDK) and DNA-dependent protein kinase
(DNA-PK) [17]. Many Rpa2 orthologs contain an N-terminal region
that is S/T-rich; however, it is not known whether these residues
in most orthologs are (1) actual targets of phosphorylation or (2)
important for RPA cellular function.
Studies of the cellular function(s) of human Rpa2 phosphoryla-
tion initially focused on the utilization of “extensive” phospho-
mutants, where all S/T residues in the Rpa2 NT were mutated to
mimic phosphorylation (all aspartic acids; Rpa2-Dx), to prevent
phosphorylation (all alanines; Rpa2-Ax), or were removed com-
pletely (deletion of ﬁrst 33 aa; Rpa2-ΔNx) [9,18]. These mutants,
along with mutation of individual or pairs of sites have been
instrumental in implicating this region as important for human
RPA function in DNA repair, cell cycle progression, and protein
interactions [9–14]. For example, it is clear that lack of hyper-
phosphorylation of the human Rpa2 NT, either by mutation of
serines 4 and 8 (S4/S8) to alanines or by inhibition of DNA-PK
activity, leads to defects in the cellular response to replicative
stress, including premature replication restart, hyper-recombina-
tion, and defective checkpoint arrest [11,14]. Also, ATR-dependent
phosphorylation of threonine 21 (T21) and serine 33 (S33) is
important for disrupting RPA association with replication centers
and preventing replication during replication stress [9,12,13].
Although none of these effects have been examined beyond a
few cell generations due to experimental complexity in human
cells, the defective phenotypes would suggest long-term detri-
mental effects on cells. This is supported by an increase in
apoptosis following replicative stress in human Rpa2-T21A/S33A
mutant cells [19].
In the budding yeast Saccharomyces cerevisiae, it is not as clear
what, if any, role phosphorylation of Rfa2 (speciﬁcally the Rfa2 N-
terminus) has on cells. Phosphorylation of this region by the
damage-speciﬁc kinase Rad53 during mitosis has been reported,
but only when the yeast cells contain a set1Δ mutation [20]. The
Rfa2 N-terminus (NT) is also phosphorylated by the meiosis-
speciﬁc kinase Ime2 during meiosis [21]. However, an unpho-
sphorylatable yeast Rfa2 NT mutant (Rfa2-Ax) has no discernible
phenotype in mitotic cell growth or in standard DNA damage
assays, indicating that this domain does not have to be phos-
phorylated for proper function of RFA in response to DNA damage
in yeast [22]. Furthermore, if mitotic phosphorylation is occurring
in this region (in a SET1 background), it is below the level of
detection by Western blotting and has not been previously
detected by mass spectrometry. Mutation of the Rfa2 NT, either
to a constitutively phospho-mimetic form (Rfa2-Dx; analogous to
human Rpa2-Dx) or to a form where the N-terminus has been
removed (Rfa2-ΔNx; analogous to human Rpa2-ΔNx), leads to
DNA damage-sensitivity [22]. However, removal of the Rfa2
N-terminus has also been reported to partially-suppress the
damage-sensitive phenotype observed in mec3Δ or set1Δ cells,
possibly through de-repression of expression of repair genes [20].
Taken together, this suggests that this domain is (1) necessary for
the damage response (at least in SET1 cells) and (2) if phosphory-
lated, may need to be dephosphorylated for a proper response to
DNA damage (based on the rfa2-Ax damage-resistant phenotype).
There is precedence for dephosphorylation being important in
human cells (and in the yeast Candida albicans; [23,24]), as human
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to dephosphorylate human Rpa2 and facilitate homologous
recombination [25]. Both budding yeast (S. cerevisiae) RFA and
human RPA must function correctly to facilitate a proper response
to DNA damage, and it is important to determine how each does
this despite apparent differences in N-terminal phosphorylation
and effects on N-terminal mutants on cellular function.
There have been many studies of RPA to characterize its
function either through binding to ssDNA or commonly found
DNA intermediates (e.g., ssDNA–dsDNA junctions) [7,26] or
through characterization of protein interactions [15]. A number
of groups have also studied the interchangeability of RPA sub-
units. These studies include exchanging yeast RFA subunits
individually with the corresponding human RPA subunit (or vice
versa) [27,28] and examination of yeast RFA in an in vitro SV40
DNA replication system [29]. It is clear that yeast RFA does not
function properly in systems that require human RPA, nor do
individual human RPA subunits function in yeast cells. Conversely,
substitutions of regions of yeast RFA subunits with the equivalent
human RPA regions can support cell growth; however, additional
phenotypes have not been examined [30]. Based on these data,
we predicted that an orthologous RPA complex might function in
yeast cells, but only if the complete complex were present. To our
knowledge, there has not been an examination of whether or not
a complete human RPA complex can function in yeast.
We examined the ability of human RPA and yeast RFA subunits
to interact and demonstrated that yeast RFA subunit interactions
are speciﬁc for other yeast subunits, and that human RPA subunit
interactions are speciﬁc for other human subunits. We postulated
that human RPA might function in yeast if it were present as a
complete complex; however, neither expression of the canonical
RPA complex nor the alternative RPA complex [28,31,32] in yeast
cells supported viability. However, examination of the human
Rpa2 NT in the context of a yeast RFA complex revealed that the
human N-terminus can substitute for the yeast Rfa2 NT. Further-
more, human Rpa2 NT phospho-mutant forms display similar
phenotypes to the equivalent yeast Rfa2 NT mutant forms. Finally,
Rfa2 containing a human Rpa2 NT is phosphorylated at residues
that are normally phosphorylated on human Rpa2 in human cells,
and phosphorylation of some sites occurs in a damage-speciﬁc
manner. Our results indicate that experimentally manipulating
human (or perhaps any eukaryotic) RPA in yeast cells may yield
important insights into RPA complex modiﬁcation and function.Results
The human RPA complex cannot substitute for the yeast
RFA complex
Yeast Replication Factor A (RFA) cannot substitute completely for
human Replication Protein A (RPA) in the in vitro SV40 replication
system [29], and individual human RPA subunits cannot substi-
tute for individual yeast RFA subunits in yeast cells [27]. However,
important regions (DBD-A and DBD-B) of human RPA subunits
can substitute for equivalent regions of yeast RFA [30]. As yeast is
a genetically amenable system for studying protein cellular
function, it was of interest to investigate if studies of human
protein behavior in yeast were feasible, especially if homologous
human proteins were able to function in place of the endogenousyeast proteins. However, to our knowledge, substituting the entire
human RPA complex for the entire yeast RFA complex in yeast had
not been tested. Furthermore, there are two forms of human RPA:
canonical RPA (consisting of Rpa1, Rpa2, and Rpa3) that supports
DNA replication and alternative RPA (consisting of Rpa1, Rpa4,
and Rpa3) that does not support DNA replication [28,32] in
human cells.
A plasmid shufﬂe assay was used to determine whether or not
the human RPA (canonical or alternative) can function in yeast
cells as the sole form of RPA present. Plasmid vectors (pJM132
derivatives) were generated where the yeast RFA1, RFA2, and RFA3
genes were substituted with the homologous human Rpa1, Rpa2
(or Rpa4), and Rpa3 genes, respectively. The expression of each
human RPA subunit gene in these constructs was driven by its
respective homologous yeast gene native promoter, and the
human RPA subunit gene expression constructs also contained a
ura3Δ::kanMX marker to select for cells containing the plasmid.
Measurement of expression of human RPA subunit mRNA from
these constructs showed that all three genes were expressed in
yeast cells (Fig. 1A). The level of mRNA expression ranged from 41
to 80% for human Rpa1, 47% for human Rpa2, and 76% for human
Rpa4 compared to their respective yeast homologs. For human
Rpa3 mRNA expression, the levels ranged from 9 to 13% compared
to yeast RFA3. This difference is somewhat exaggerated, because
these yeast cells contain both a chromosomal copy and a plasmid
copy of the RFA3 gene; however, the mRNA expression ratio of
human Rpa3 mRNA to yeast RFA3 mRNA was consistently the
lowest. Since reliable antibodies are readily available for human
Rpa1 and Rpa2, protein expression for these subunits was also
examined. Fig. 1B showed that human Rpa1 protein is detected
when cells expressed either the canonical RPA plasmid or the
alternative RPA plasmid (Fig. 1B). Furthermore, human Rpa2 could
be detected when the canonical RPA expressing plasmid was
present in the cells (Fig. 1B).
A spot assay was performed to determine if yeast cells contain-
ing only a human RPA-expressing plasmid could survive. Human
RPA-expressing cells were grown overnight in YPDþG418,
counted, serial diluted, and plated onto YPDþG418 (demonstrates
that cells originally contained plasmid expressing human RPA),
SD-HLU (required to demonstrate that control cells contained
vectors with both WT yeast RFA1 and RFA2 genes), and SDþ5-FOA
(demonstrates the ability of cells to lose the WT yeast RFA1, RFA2,
and RFA3-expressing pJM132 plasmid, which all cells contain).
Only cells that have a form of RFA or RPA that can support DNA
replication in yeast will show growth on 5-FOA. The control cells
containing WT RFA1 and RFA2 vectors showed growth on 5-FOA-
containing plates (Fig. 1C; row 1), indicating complementation of
chromosomal rfa1Δ and rfa2Δ. Two independent clones expres-
sing either canonical RPA (Fig. 1C; rows 2–3) or alternative RPA
(Fig. 1C; rows 4–5) did not display observable growth on 5-FOA
plates, indicating that expression of the either human RPA
complex in yeast cells as the sole source of RPA does not function
to support cell viability.
Lack of inter-species interactions among the human RPA
and yeast RFA subunits
The inability of individual human RPA subunits to function in
place of their respective homologs in yeast suggested that
complex formation might not occur properly between inter-species
Fig. 1 – Human RPA does not support viability in yeast cells. (A) Quantitative PCR measurement of yeast and human RPA subunit
gene expression. mRNA expression was measured for all yeast and human RPA subunit genes for RMY122-A (RMY Only; no
additional plasmid), RMY122-A expressing human canonical RPA (Rpa1, Rpa2, and Rpa3) genes (RMY122þcRPA), and RMY122-A
expressing human alternative RPA (Rpa1, Rpa4, and Rpa3) genes (RMY122þaRPA). All values were normalized to expression of the
yeast UBC6 gene. (B) Detection of human Rpa1 and Rpa2 expression in yeast cells. Using the same three strains in (A), protein
expression was examined for human Rpa1 (hRpa1), Rpa2 (hRpa2), yeast Rfa1 (yRfa1), and Rfa2 (yRfa2) via Western blotting (WB).
EXP denotes which expression plasmid the yeast cells contained. (C) Plasmid shufﬂe to examine human canonical and alternative
RPA function in yeast cells. The ability of cells to lose the pJM132 vector, which can only occur if the human RPA complex (cRPA or
aRPA) can substitute for yeast RFA function, was assessed by spot assay to SD media containing 0.8 μg/mL 5-FOA. Two independent
transformants expressing canonical human RPA and alternative human RPA are shown, as well as a positive control (Yeast RFA) in
which the WT yeast genes RFA1 and RFA2 were co-transformed into RMY122-A cells. YPDþG418 is a control to show that cells
originally contained the “humanized” vector, and -HLU is a control to show that cells originally contained yeast RFA1 and RFA2
vectors.
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interact. To make this determination, we utilized a yeast two-
hybrid assay and examined the ability of the large (70 kDa)
subunit of yeast RFA (Rfa1) or human RPA (Rpa1) to interact with
their homologous partner subunits. Yeast Rfa1 and human Rpa1
were chosen, because these are the only subunits that do not
display auto-activation of the reporter genes (i.e., false-positive
interaction). In Fig. 2A, four independent yeast Rfa1 constructs
fused to the lexA DNA binding domain (BD) were examined for
interactions with each of the human RPA subunits fused to the
B42 transcriptional activation domain (AD) or an empty AD vector
(as a control). The lack of growth on SD-HTUL in the presence of
an empty AD vector indicates no auto-activation from any of the
BD-Rfa1 fusion constructs. Rfa1-FLAB is a control that is lacking
the C-terminal 208 amino acids (DBD-C) and is incapable of
forming a complex with yeast Rfa2 or Rfa3 [33]. The remaining
three BD-Rfa1 constructs express full-length Rfa1, however, eachis slightly different (i.e., expression is driven from a different
promoter or the amino acid immediately preceding the ﬁrst
codon of Rfa1 is different). For the BD-Rfa1 (pPM07), expression
is driven from a galactose-inducible promoter, and we observe
that its overexpression leads to a dominant-negative phenotype
for growth (i.e., lack of growth on SG-HTUL and reduced growth
on SG-HTUþX-gal). However, this construct normally leads to
blue color for the limited growth on SG-HTUþX-gal when in
combination with yeast AD-Rfa2 or AD-Rfa3 [33]. There is no blue
color when this bait construct (BD-Rfa1; 07) is examined with the
human RPA subunits. The other two bait constructs, pSJH101 and
pENM17, express Rfa1 constitutively from the ADH1 promoter.
There is no blue color observed when combined with any of the
human RPA subunits (Fig. 2A; SG-HTUþX-gal); however, very
slight growth is observed on SG-HTUL plates for AD-Rpa2 and
even fainter growth is observed for AD-Rpa3 when combined
with BD-Rfa1 expressed from pENM17. This would indicate a very
Fig. 2 – Examination of inter-species RPA subunit interactions. (A) Yeast Rfa1 does not interact with human RPA subunits. Two-
hybrid analysis was performed by co-transforming EGY48 cells with bait (BD) plasmids (PADH1-lexA) expressing yeast RFA1 and prey
(AD) plasmids (PGAL-B42-HA) expressing each possible human RPA subunit. Included in each co-transformation was the reporter
plasmid pSH18-34 (8xOlexA-lacZ). Interaction was measured for three independent transformants by the ability to grow on
synthetic media containing 2% galactose and lacking histidine, tryptophan, uracil, and leucine (SG-HTUL). Qualitative interaction
strength was measured by replica plating to SG-HTUþX-gal. FLAB¼BD-Rfa1-FLAB (missing DBD-C; does not interact with yeast Rfa2
or Rfa3); 07¼BD-Rfa1 expressed from galactose-inducible promoter; 101¼BD-Rfa1 expressed from constitutive promoter; 17¼BD-
Rfa1 constitutively expressed with leucine (instead of histidine) immediately preceding Rfa1 start codon. YPD plate is a control for
growth after replica plating. (B) Human Rpa1 does not interact with yeast RFA subunits. Experiment performed as in (A), except bait
plasmid was human Rpa1 and prey plasmids contain either human RPA subunits or yeast RFA subunits. SD-HTU plate shown to
verify that each patch contained a bait, prey, and reporter plasmid. Again, growth on SG-HTUL indicates interaction, and blue color
of SG-HTUþX-gal represents strong interaction. (C) Rpa2 or Rpa4 is required for Rpa1 and Rpa3 to interact. No interaction between
Rpa1 and Rpa3 was observed in (B) (SG-HTUL and SG-HTUþX-gal plates); however, when a pJM132 derivative expressing either
Rpa2 or Rpa4 (extra plasmid) was co-transformed, Rpa1 and Rpa3 now display weak interaction, as indicated by growth on SG-
HLTU. SG-HTU is a growth control; SD-HTUL is to detect auto-activation. Although auto-activation complicates analysis in cells
expressing Rpa2 or Rpa4 only, cells expressing Rpa2þRpa3 or Rpa4þRpa3 show reduced auto-activation, yet display increased
growth on SG-HTUL (i.e., when AD-Rpa3 expression is induced).
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Rpa2 and an even weaker interaction between yeast Rfa1 and
human Rpa3. These interactions are very weak compared to those
observed for yeast Rfa1 and yeast Rfa2 or Rfa3, where blue color
on SG-HTUþX-gal media and strong growth on SG-HTUL for
pSJH101 and pENM17 normally occurs [33].
The reciprocal experiment was performed using human Rpa1 as
the bait. In Fig. 2B (bottom half), no growth was observed for
human BD-Rpa1 combined with yeast AD-Rfa1, AD-Rfa2, orAD-Rfa3 on media diagnostic for interaction (SG-HTUL). Further-
more, no blue color was observed for any of these combinations
on SG-HTUþX-gal media. This demonstrates that the human Rpa1
does not detectably interact with any of the yeast RFA subunits,
and explains why substitution of any individual yeast subunit by
the homologous human subunit would not function properly.
To demonstrate that the human subunits interact with one
another, we also examined human BD-Rpa1 in combination with
AD-tagged versions of each human RPA subunit (Fig. 2B; top half).
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blue color on SG-HTUþX-gal) with Rpa2 and Rpa4, but not Rpa3
(Fig. 2B; top half).
It was previously shown that recombinant human Rpa2 and
Rpa3 form a stable subcomplex that is soluble and can be readily
puriﬁed [34]. It was also shown that siRNA knockdown of human
Rpa1 only negatively affects mRNA/protein expression of Rpa1,
but that knockdown of human Rpa2 negatively affects detection
of cellular Rpa2 and Rpa1 proteins [9,28,35,36]. This also supports
the idea of an Rpa2-Rpa3 subcomplex in the cell. Our data
suggests that human Rpa2 (or Rpa4) is the subunit mediating
the interaction of this subcomplex with human Rpa1, as the
interaction between human Rpa1 and Rpa2 (or Rpa4) is occurring
in yeast cells that are not expressing human Rpa3. To verify this,
we expressed human Rpa2 or Rpa4 (pPLG35 or pPLG36; extra
plasmid) in addition to BD-Rpa1 and AD-Rpa3 in yeast cells.
Interpretation for whether human Rpa2 or Rpa4 mediated inter-
action with AD-Rpa3 was complicated by the observation of auto-
activation (growth on SD-HTUL; Fig. 2C; rows 2–3) when either
Rpa2 or Rpa4 was expressed from the extra plasmid. However,
this observation does lend further support for the interaction of
human Rpa2 or Rpa4 with Rpa1, because BD-Rpa2 or BD-Rpa4
alone are also known to cause auto-activation [31,33,37]. In this
case, we propose that recruitment of Rpa2 or Rpa4 by BD-Rpa1 is
having a similar activation effect. Human Rpa2 or Rpa4 were also
expressed from plasmids expressing human Rpa3. This appeared
to minimize the auto-activation effect observed above (minimalFig. 3 – Domain swapping of the yeast Rfa2 loop 3–4 or N-termina
(A) Sequence comparison of the yeast Rfa2, human Rpa2, and huma
sequence on either side of the loop region is displayed. Also denote
of Rfa2 that have been reported through mass spectrometry analy
¼weakly similar properties. (B) DNA damage phenotypes of Rfa2 lo
measured by growing WT RFA2-expressing (y2NT), loop hybrid (h2
h4NT)-expressing, and rfa1-t11-expressing (damage-sensitive contr
numbers of cells. The diluted cells were then spotted onto rich m
methyl methanesulfonate (0.015% MMS), camptothecin (1 μg/mL C
Results from additional concentrations of damaging agents are sh
Rpa2, and human Rpa4 N-termini (with gaps removed). Gaps were
Fig. S1B for the ﬁrst 38 aa residues to display that known sites (blac
of phosphorylation lie in similar positions.growth on SD-HTUL; Fig. 2C; rows 4–5). However, when AD-Rpa3
expression was induced by addition of galactose in these cells,
growth on SG-HTUL was noticeably increased (Fig. 2C). Here
activation is most likely due to recruitment of AD-Rpa3, through
an interaction with Rpa2 or Rpa4.
The loop 3–4 region of Rpa2 or Rpa4 does not affect yeast
Rfa2 function
Since the human RPA complex cannot substitute for the yeast RFA
complex, a domain swap approach was taken to determine the
importance of two different regions of human Rpa2 or Rpa4 by
examining their effects in yeast cells. The ﬁrst region was the loop
3–4 (L34) region of human Rpa2 [38] or Rpa4 [28]. In the
structure of human Rpa2, this loop most likely represents a
structurally-disordered ﬂexible region, as a deﬁned structure for
this region is only observed in one of the deposited crystal
structures for human Rpa2 [38]. The L34 region is also of interest,
because it is at least partially responsible for the difference in
in vitro and cellular replication function between human Rpa2
and Rpa4 [28,32]. The major difference between the human Rpa2
and Rpa4 L34 regions lies in the apparent overall charge of the
loop. In human Rpa2, this region contains a number of aspartic
acid (D) and glutamic acid (E) residues, whereas in the human
Rpa4 L34 region, there are more arginine (R) and lysine (K)
residues (Fig. 3A) [28,31]. In yeast Rfa2, this region contains an
additional 14–15 amino acid residues compared to human Rpa2l region with the analogous human Rpa2 or Rpa4 region.
n Rpa4 loop 3–4 regions. Alignment of conserved amino acid
d (black highlight with white font) are sites of phosphorylation
sis [39–41]. *¼ identical residue; :¼strongly similar properties;.
op 3–4 or N-terminal swaps. Sensitivity to DNA damage was
L34 or h4L34)-expressing, N-terminal (NT) hybrid (h2NT or
ol) cells and serial diluting (three-fold dilutions) equivalent
edia (YPD) or rich media containing the DNA damaging agents
PT), hydroxyurea (80 mM HU), or phleomycin (5 μg/mL PHL).
own in Fig. S1. (C) Sequence alignment of the yeast Rfa2, human
removed from the T-COFFEE sequence alignment shown in
k highlights with white font) or putative sites (grey highlights)
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identiﬁed by mass spectrometry to contain serines (S) and a
tyrosine (Y) that are phosphorylated [39–41], although only one
(S122) has been validated and demonstrated to be phosphory-
lated by Mec1 (the yeast ATR homolog) in response to DNA
damage [42,21] (Fig. 3A). Serine 122 currently has no obvious role
in the mitotic DNA damage response, but may be important for
crossover frequency during meiosis [43].
To determine whether the human Rpa2 or Rpa4 L34 regions
could play similar roles in yeast with respect to supporting or
preventing cellular DNA replication, respectively, the human Rpa2
or Rpa4 L34 encoding region was cloned into yeast RFA2 in place
of the region encoding the normal Rfa2 L34 region (called rfa2-
h2L34 or rfa2-h4L34). Plasmid shufﬂe was then used to assess the
viability of yeast cells expressing the L34 domain-swapped forms.
Rfa2 containing either human Rpa2 L34 or Rpa4 L34 supports
replication function, as cells were recovered on 5-FOA-containing
media. Since cells expressing these mutant Rfa2 forms could be
readily recovered, it was important to determine if there is an
effect on the response to DNA damage. In Fig. 3B, it was observed
that the cells expressing Rfa2-h4L34 do not display any obvious
DNA damage sensitivity and are indistinguishable from cells
containing WT Rfa2 in that respect (Fig. 3B and S1A). The cells
expressing Rfa2-h2L34 do show a slight DNA damage sensitivity,
observed as slightly smaller microcolony growth on media con-
taining hydroxyurea (HU) (Fig. 3B) and reduced growth on media
containing higher concentrations of camptothecin (CPT) and
phleomycin (PHL) (Fig. S1A). However, this sensitivity is minor
in comparison to that observed for the control cells expressing
yeast Rfa1-t11 (Fig. 3B and S1), a mutation previously character-
ized to have a strong defect in DNA repair [44–46]. We conclude
that the L34 region is not important for yeast Rfa2 function in
DNA replication or repair, and that phosphorylation of previously
identiﬁed sites in this region is also not important in replication
or repair, as they are no longer present in these hybrid proteins.
This does not rule out the possibility of phosphorylation of serines
(S) or threonines (T) in the human Rpa2 or Rpa4 loops; however,
any effect is minimal at best.
The human Rpa2 or Rpa4 N-terminus supports Rfa2
cellular function in replication and repair
The phosphorylation of the N-terminus of human Rpa2 has been
well-studied with respect to sites of phosphorylation, kinases
involved, and physiological consequences associated with perturba-
tion of phosphorylation [15]. The physiological consequences of
mutating serines/threonines in this region, especially S4, S8, T21,
and S33, to alanines include premature replication restart, defective
checkpoint arrest, hyper-recombination, and mitotic chromosome
segregation defects [11–14,19]. Hyper-phosphorylation has also been
demonstrated to disrupt RPA interaction with Mre11 [10] and
promote increased interaction with Rad51 and Rad52 [47].
We have recently demonstrated that phosphorylation of the
yeast Rfa2 N-terminus is unimportant for the cellular response to
DNA damage in standard DNA damage assays; however, the
presence of this domain is required for a proper response to DNA
damage in mitotically-growing yeast cells [22]. In fact, phosphor-
ylation of this region is undetectable via Western blotting methods,
and thus far has not been identiﬁed by mass spectrometry in
mitotic cells. In meiotic yeast cells, phosphorylation occurs at S27by the meiosis-speciﬁc kinase Ime2 and perhaps at one other
location within the yeast Rfa2 N-terminus as determined by mass
spectrometry [21]. Since phosphorylation of the Rfa2 NT does not
appear to be required for replication or repair (as assayed), we
postulated that the human Rpa2 or Rpa4 NT would support cell
growth (i.e., RFA function) in yeast cells. To test this, we swapped
the yeast Rfa2 NT with the N-terminus of human Rpa2 or Rpa4.
Shown in Fig. S1B is a T-COFFEE [48] alignment of the yeast Rfa2
and human Rpa2 and Rpa4 N-terminal regions. Both of the
domains are serine/threonine-rich, and when spaces inserted by
T-COFFEE are manually removed from this alignment (Fig. 3C), it
appears that the serines/threonines are located at similar residue
positions. However, the sequence context surrounding these ser-
ines/threonines varies between the subunits. Cells expressing
chimeric RFA2 genes encoding the human Rpa2 N-terminus
(h2NT) or Rpa4 N-terminus (h4NT), cells are able to survive the
loss of pJM132, indicating proper cellular function of the hybrid
Rfa2 forms in unstressed conditions. This allowed for the recovery
of mutant cells, where the only form Rfa2 being expressed is the
hybrid form. The recovered rfa2-h2NT and rfa2-h4NT cells were
then subjected to DNA damaging agents (Fig. 3B and S1A). Similar
to the results observed for the loop 3–4 domain swaps, both rfa2-
h4NT and rfa2-h2NT cells are nearly indistinguishable from WT
RFA2 cells with respect to resistance to DNA damage. However,
both mutants show a very slight sensitivity that is only observed
when very high concentrations of damaging agents are used (Fig.
S1A). This sensitivity is not nearly as severe as the sensitivity
observed for rfa1-t11 cells, but it is more severe than that observed
for the loop domain hybrids.
Human Rpa2 N-terminal chimeric mutants display DNA
damage phenotypes similar to analogous Rfa2 N-terminal
mutants
One way to study the effects of phosphorylation (or lack thereof)
on cellular function of a protein is through the use of phospho-
mimetic and unphosphorylatable mutant forms. In human cells,
hyper-phosphorylation of human Rpa2 is correlated with induc-
tion of DNA damage, and phospho-mutant forms lead to physio-
logical defects in RPA cellular function. This approach has been
utilized in human cells not only to elucidate the physiological
importance of human Rpa2 modiﬁcation, but also in yeast cells to
elucidate the importance of the analogous domain in yeast Rfa2
[22]. It was determined that deletion of the yeast Rfa2 N-terminus
(rfa2-ΔNx) results in DNA damage sensitivity, whereas an
N-terminal unphosphorylatable form (rfa2-Ax) is DNA damage-
resistant. This implies that the presence of the domain is what
was important, not its modiﬁcation. However, a constitutive
phospho-mimetic N-terminal form of Rfa2 (rfa2-Dx) also displays
sensitivity to DNA damage, which suggests that if the N-terminus
were phosphorylated, its dephosphorylation must also be impor-
tant in the damage response. Given that phosphorylation of the
Rfa2 N-terminus is undetectable and that an unphosphorylatable
Rfa2 NT mutant is not damage-sensitive in S. cerevisiae, it appears
that a highly negatively-charged domain might actually be detri-
mental to yeast Rfa2 function.
We asked whether similar human Rpa2 N-terminal forms,
when attached to yeast Rfa2 (rfa2-h2Dx, rfa2-h2Ax, and rfa2-
h2ΔNx), affect hybrid Rfa2 function in a similar manner to yeast
Rfa2 phospho-mutants. The hybrid phospho-mutant forms
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human N-terminal phospho-mutant form supports RFA replica-
tive function in unstressed cells. The hybrid mutant cells were
exposed to DNA damaging agents, and DNA damage-sensitivity
was examined. rfa2-h2Ax cells displayed a damage resistance that
was only very slightly sensitive compared to either rfa2-Ax
(designated rfa2-y2Ax) cells or WT RFA2 cells (Fig. 4B and S2).
This was despite the observation that rfa2-h2Ax cells grow slower
than rfa2-y2Ax or WT RFA2 cells. Cells where the Rfa2 N-terminuswas deleted (rfa2-ΔNx; designated rfa2-y2ΔNx) or where the well-
studied human N-terminus was deleted (rfa2-h2ΔNx; deletion of
ﬁrst 33 amino acids of human Rpa2 with aa 34–38 attached to
yeast Rfa2) both displayed a moderate sensitivity to damaging
agents (Fig. 4B and S2). Finally, rfa2-h2Dx cells displayed the
highest sensitivity to DNA damage of all of the hybrid phospho-
mutants (Fig. 4B and S2). The rfa2-h2Dx cells were more damage-
sensitive than the corresponding mutation in yeast Rfa2 (rfa2-Dx;
designated rfa2-y2Dx) and nearly as sensitive as rfa1-t11 cells.
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y2Dx, both are DNA damage sensitive. Overall, the degrees of
sensitivity are slightly different, but the pattern of sensitivity is
similar between analogous yeast and hybrid mutant forms
(Fig. 4C), suggesting that the human N-terminal mutant forms
function similar to that observed for the yeast N-terminal mutant
forms, at least in yeast cells.The human Rpa2 N-terminus is phosphorylated in yeast
cells in a manner similar to that observed in human cells
The human Rpa2 N-terminal domain is phosphorylated on two
sites (S23 and S29) during the cell cycle by CDK and is phos-
phorylated on multiple sites (e.g., S4, S8, S12, T21, S33) by ATR,
ATM, and DNA-PK in response to DNA damage [17]. It is clear that
more than one residue (and potentially all) are phosphorylated
concurrently on a single human Rpa2 N-terminus, as indicated by
a several kilodalton shift in species. Phosphorylation also appears
to be sequential or primed in human cells, as phosphorylation of
some sites requires previous phosphorylation of others [12,17].
Protein expression and phosphorylation were examined for the
hybrid Rfa2 proteins. In Fig. 5A, it was observed that hybrid Rfa2
containing the human Rpa2 NT is post-transnationally modiﬁed in
unstressed mitotically-growing cells. By comparison, no additional
robust species are observed above the predominant Rfa2 species for
the hybrid Rfa2 proteins containing the human Rpa2-Dx, Rpa2-Ax,
Rpa2-ΔNx, or Rpa4 N-terminus (Fig. 5A). This suggests that post-
translational modiﬁcation(s) occurs in the human Rpa2 N-terminus
during the normal cell cycle in yeast, and that it is mapped to the
N-terminus of human Rpa2. As there are two sites phosphorylated
by CDK in human cells during S-phase of the cell cycle, we propose
that these modiﬁcations might also be occurring in yeast, perhaps by
the homologous kinase Cdc28.
Hybrid Rfa2-expressing cells were also examined for additional
phosphorylation upon induction of DNA damage by treatment of
cells with methyl methanesulfonate (MMS). As a marker for DNA
damage induction and G2/M checkpoint establishment [45],
Rad53 phosphorylation was also measured. Upon DNA damage,
Rad53 was phosphorylated in cells containing any form (WT orFig. 4 – Domain swapping of the yeast Rfa2 N-terminus with hum
human Rpa2. (A) Schematic representation of the human N-termina
phosphorylation were either mutated to aspartic acids (Dx) to mim
or the N-terminus was removed (ΔNx). Yeast forms are designated
forms are designated with the preﬁx h and are denoted by the color
Amino acid positions of serines/threonines for yeast Rfa2 or huma
(B) DNA damage phenotypes of domain swaps compared to their ana
were generated that expressed the yeast Rfa2 N-terminus swapped
rfa2-h2NT or rfa2-h4NT, respectively (examined in Fig. 3B). RFA2 chi
mutant forms of the Rpa2 N-terminus in which every serine/threo
aspartic acids (rfa2-h2Dx), alanines (rfa2-h2Ax), or the ﬁrst 33 aa are
mutations are designated as rfa2-yDx, rfa2-y2Ax, and rfa2-y2ΔNx, r
measured as described in Fig. 3B. (C) Qualitative ranking of DNA dam
or aa substitution) forms were ranked from most DNA damage-re
spot assays on media containing varying concentrations of DNA dam
right describe the N-terminus of each cluster of mutants.ﬃdesign
approximately equal with respect to damage sensitivity phenotypehybrid) of Rfa2. This not only indicates that DNA damage is
occurring in these cells, but also that none of the hybrid forms
affects the establishment of the G2/M checkpoint upon DNA
damage induction [49]. Analysis of WT or hybrid Rfa2 reveals
additional post-translational modiﬁcation of Rfa2-h2NT (Fig. 5B).
Furthermore, we conclude that the additional observed PTM(s) is
phosphorylation, as it is not observed for any of the human Rpa2
NT serine/threonine mutant hybrid Rfa2 forms (Fig. 5B) in
response to DNA damage. We conclude that the human Rpa2
N-terminus can be phosphorylated in the context of the yeast RFA
complex by yeast kinases in yeast cells.
We demonstrated that the human Rpa2 NT is phosphorylated in
unstressed cells, and that an additional site(s) is phosphorylated
upon treatment of cells with MMS. We also demonstrated that
Rfa2 NT mutants display sensitivities to not only MMS, but also to
other DNA damaging agents, such as CPT, HU, and PHL (Fig. 4B), all
of which have a different mode of action to generate DNA damage.
To address whether or not the human Rpa2 (or Rpa4) NT is
phosphorylated under other damage conditions, we examined
phosphorylation of Rfa2-h2NT and Rfa2-h4NT hybrid proteins. It
was observed that not only is Rfa2-h2NT post-translationally
modiﬁed in response to MMS, it is also post-translationally
modiﬁed in response to CPT and PHL (Fig. 5C; left half). Apparent
post-translational modiﬁcation was not observed when cells were
treated with HU (Fig. 5C; left half). Examination of Rfa2-h4NT
post-translational modiﬁcation after DNA damage indicated that
this hybrid protein was also modiﬁed in response to CPT and PHL,
but not HU (Fig. 5C; right half). However, the human Rpa4
N-terminus does not appear to be as strong of a phosphorylation
target as the human Rpa2 N-terminus in S. cerevisiae (Fig. 5C).
The fact that either hybrid protein was not overtly modiﬁed in
response to HU was intriguing, given that HU in human cells
elicits readily observable Rpa2 N-terminal hyper-phosphorylation
[50]. To determine if we had damaged the DNA sufﬁciently in cells
treated with HU, we measured whether checkpoint activation had
occurred by examining phosphorylation of Rad53 (yeast homolog
to human Chk2). As demonstrated in Fig. 5C, HU-treated cells
display signiﬁcant phosphorylation of Rad53, indicating that there
was sufﬁcient DNA damage in the cells. We also measured Rad53
phosphorylation for the other damaging-agent treatments.an Rpa4, human Rpa2, or extensive phospho-mutant forms of
l hybrid proteins examined. Sites (known or putative) of
ic phosphorylation, alanines (Ax) to be non-phosphorylatable,
with the preﬁx y and are denoted by the color blue; human
purple. The rfa1-t11 mutation (K45E) is in DBD-F of yeast Rfa1.
n Rpa2 are denoted above or below their respective N-termini.
logous yeast N-terminal mutants. Yeast RFA2 chimeric mutants
for the equivalent human Rpa2 or Rpa4 N-terminus, denoted as
meric genes were also generated to express extensive phospho-
nine (S/T) within the ﬁrst 33 aa of human Rpa2 are mutated to
deleted (rfa2-h2ΔNx), as represented in (A). The equivalent rfa2
espectively. Sensitivity to DNA damage of Rfa2 hybrid cells was
age resistance of rfa2 N-terminal hybrid forms.Mutant (hybrid
sistant to most DNA damage-sensitive based on the results of
aging agents (Figs. 3 and 4B, S1A, and S2). Designations to the
ates that the mutant above and below the symbol are
.
Fig. 5 – Hybrid Rfa2 is phosphorylated on its N-terminus. (A)
Phosphorylation occurs in undamaged cells and is speciﬁc to the
human Rpa2 N-terminus. Cells containing hybrid forms of Rfa2
were grown to exponential phase and protein was collected
using the method described by Kushnirov [63]. Western
blotting with anti-yeast Rfa2 antibody reveals slower-
migrating species (denoted by black arrows) that are not
detected in Rfa2 phospho-mutant hybrid forms. Rfa1 blotting
was performed to demonstrate that yeast Rfa1 expression was
unaffected, indicating proper complex formation. (B) DNA-
damaged cells display additional N-terminal phosphorylation
on the human N-terminus. Cells were grown as in (A); however,
half of each cell culture was treated with 0.03% methyl
methanesulfonate (MMS; denoted above each lane;
0¼none,þ¼added). Protein separation and detection were
performed as in (A), and a more intense species (denoted by
white arrow) is detected by anti-yeast Rfa2 antibody. Again, no
additional species are observed for any of the human Rpa2
N-terminal S/T mutants in either unstressed or stressed
conditions. Blot below shows Rad53 (lower grey arrow) and
activated Rad53 (upper black arrow) as a marker indicating
that cells were damaged and initiated a G2/M checkpoint. A
background species is observed in all lanes and denoted with
an asterisk. (C) Phosphorylation of the Rfa2-h2NT or Rfa2-h4NT
hybrid proteins in response to different DNA damaging agents.
Cells were grown to exponential phase and either left
untreated (U) or treated with 0.03% methyl methanesulfonate
(M), 20 μg/mL camptothecin (C), 400 mM hydroxyurea (H), or
20 μg/mL phleomycin (P) for 4 h. For hybrid Rfa2 detection,
30 μg of total protein were loaded per lane. For Rad53
detection, 120 μg of total protein were loaded per lane. Black
arrows denote phosphorylated species of the hybrid Rfa2 or
Rad53 proteins.
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Rad53 phosphorylation; however, CPT treatment did not. Despite
the apparent lack of Rad53 activation by CPT, Rfa2-h2NT and Rfa2-
h4NT were signiﬁcantly modiﬁed with this treatment (Fig. 5C).
Finally, PHL-treatment appeared to elicit a strong Rfa2-h2NTmodiﬁcation phenotype, and Rad53 was phosphorylated in these
cells. However, Rad53 (either modiﬁed or unmodiﬁed) was not
easily detected in PHL-treated cells, suggesting its modiﬁcation/
stability is different than when cells are treated with other
damaging agents. These data demonstrate that there is no
correlation between Rad53 and Rfa2-h2NT phosphorylation
(Table 1). This is further substantiated by the observation that
the damage-treatments elicit the same response with respect to
Rad53 phosphorylation, regardless of whether the yeast Rfa2
form is WT, h2NT, or h4NT (Fig. 5C).
There are other observations worth noting. First, MMS treat-
ment of cells appears to elicit an additional phenotype—increased
expression of Rfa2 (or hybrid) protein (Fig. 5C; 30 μg total protein/
lane). This increase in expression was not observed for any of the
other damage treatments. Second, PHL (and perhaps CPT) treat-
ment results in an apparent increase in the abundance of the
higher mobility species of post-translationally modiﬁed Rfa2-
h2NT and Rfa2-h4NT relative to the unmodiﬁed species. Although
qualitative, this suggests not only that different DNA damaging
agents (and by inference, different types of damage) are eliciting
different damage responses in the cells, but also that Rfa2-h2NT is
being modiﬁed differently in response to these agents. This
indicates that the Rfa2-h2NT hybrid could be a useful tool for
assessing these differences in responses, especially after the
kinases have been identiﬁed that target the Rfa2-h2NT domain.
Does phosphorylation of the hybrid Rfa2-h2NT in yeast cells
occur at the same sites and same (cell cycle and damage) conditions
as human Rpa2 in human cells? To address this, Western blotting
was performed with phospho-speciﬁc antibodies to human Rpa2
serines 4 and 8 (anti-pS4/pS8), serine 12 (anti-pS12), threonine 21
(anti-pT21), serine 29 (anti-pS29), and serine 33 (anti-pS33). Fig. 6A
shows two independent experiments examining WT (y2NT) or
hybrid Rfa2 (h2NT) protein extracted from unstressed and stressed
cells (treated with MMS to induce DNA damage) for human Rpa2
N-terminal phosphorylation at serines 4 and 8. Although the anti-
yeast Rfa2 antibody recognizes both the WT and hybrid forms in
either condition (left blots), the only form that is detected by the
anti-pS4/S8 antibody is the Rfa2-h2NT form. Furthermore, this
hybrid form is only detected when the cells have been treated
with MMS. We conclude that phosphorylation is occurring in the
N-terminal region of the hybrid Rfa2-h2NT, and that serines 4 and 8
are two of the targets.
In human cells, phosphorylation of the Rpa2 N-terminus at
serines 4 and 8 is downstream of almost all other phosphoryla-
tion events in this region [11,12,17]. To address if this might be
true for hybrid Rfa2-h2NT in yeast cells, phosphorylation at other
sites using phospho-speciﬁc antibodies was examined. Fig. 6A
shows that the phospho-speciﬁc antibodies (right half) only
recognize hybrid Rfa2. Furthermore, phosphorylation of Rfa2-
h2NT is detected in both unstressed and stressed conditions for
T21, S29, and S33 (Fig. 6A), and damage-speciﬁc phosphorylation
was observed for S12 and S4/S8 (as described above). Thus,
phosphorylation of Rfa2-h2NT in yeast cells occurs at the same
sites where phosphorylation is observed in human cells.Discussion
Replication Protein A (RPA) functions in the cell not only through
binding single-stranded DNA (ssDNA), but also through its role as
Table 1 – Qualitative summary of phosphorylation observed under different damage conditions.
Protein Mitotic growth Damage treatment
0.03% Methyl
methanesulfonate (MMS)
20 μg/mL
Camptothecin (CPT)
400 mM
Hydroxyurea (HU)
20 μg/mL
Phleomycin (PHL)
Rad53 0 þþþþ 0 þþþþþ þþ
Rfa2 0 0 0 0 0
Rfa2-h2NT þ þþþ þþþþ þ þþþþþ
Rfa2-h4NT 0 þþ þþ 0 þþþ
0¼No detectable post-translational modiﬁcation; number of þ represents the intensity of the post-translationally modiﬁed species compared the
unmodiﬁed species.
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intermediates correctly. Since RPA functions in multiple processes
(DNA replication, repair/recombination, cell cycle regulation), it is
presumed that its function is different for each of these processes.
It is also presumed that RPA must somehow be regulated to
function in different capacities. Post-translational modiﬁcation is
a common method by which a protein’s function can be quickly
regulated, and human RPA is post-translationally modiﬁed, espe-
cially in response to DNA damage. In human tissue culture cells,
this predominantly occurs as hyper-phosphorylation of the Rpa2
N-terminus. It is clear that phosphorylation of the human Rpa42
N-terminus is important to prevent hyper-recombination, pro-
mote checkpoint arrest, and delay replication restart; however,
this is studied over the course of a few generations in human cells
and the long-term consequences of such defects have not been
directly examined due to technical limitations of knockdown and
expression studies. In budding yeast, consequences of RFA subunit
mutation can be examined over the course of 50 or more
generations, allowing for the assessment of physiological con-
sequences of defects in DNA processes; however, hyper-
phosphorylation of the Rfa2 N-terminus does not occur in
response to DNA damage in budding yeast. It is unclear how the
yeast Rfa2 (or RFA) is regulated in response to DNA damage, but it
is clear that lack phosphorylation of the N-terminus in response
to DNA damage is not obviously detrimental over the long-term
(at least 50 cell divisions).
In an attempt to study human RPA function in a simpler system
(yeast), we explored the possibility of replacing a complex for a
complex, rather than a subunit for a subunit. Unfortunately, the
human RPA complex (in either the canonical or alternative form)
does not support viability in yeast cells and precludes further
study. Human Rpa1 and Rpa2 mRNA expression levels are about
50% of the levels of their homologous RFA genes, and we can
clearly detect substantial full-length protein for each expressed in
yeast cells. We can conclude that human Rpa3 and Rpa4 are also
expressed in yeast cells through indirect means. If Rpa4 or Rpa3
were not expressed from the plasmid, addition of the plasmid
expressing Rpa4 only would not show auto-activation for BD-
Rpa1, and addition of the plasmid expressing Rpa4 and Rpa3
would not quench some of the auto-activation observed in Fig. 2C.
We cannot rule out that human Rpa3 mRNA (and by inference
protein) expression levels (10% of yeast RFA3) might be too low
to support viability. It is also conceivable that the human Rpa1
and Rpa2 expression levels might be below the threshold tosupport viability. However, given that the human RPA subunit
genes are driven from their homologous yeast gene promoters,
the only way to address whether lack of complementation is due
to expression levels in the future would be through the use of an
inducible promoter (e.g., galactose-inducible) or a high-copy
plasmid to produce high-level expression of human RPA genes
(most likely much higher than physiological, endogenous RFA
gene expression).
Through these studies, we have provided evidence that hetero-
trimeric complex formation is mediated through Rpa2 (or Rpa4),
and that Rpa1 interaction with Rpa2 (or Rpa4) does not require
the presence of Rpa3. This does not preclude the possibility of
human Rpa2 interacting with yeast Rfa3 to form a subcomplex
that can interact with human Rpa1 (we cannot currently measure
this due to auto-activation observed for all bait constructs
containing human or yeast Rpa2 or Rpa3). However, human
Rpa1 does not interact with yeast Rfa3, suggesting again that
human Rpa2 is the main driving force for complex formation. This
is consistent with the idea of a stable subcomplex of Rpa2 and
Rpa3 in human cells that can then interact with Rpa1 [34]. Our
data indicate that subcomplex interaction with human Rpa1 is
predominantly through Rpa2, or alternatively that Rpa2 (or Rpa4)
expression is what stabilizes Rpa3 to allow interaction with Rpa1.
Loop 3–4 function appears to be human cell-speciﬁc
Although whole complexes could not be swapped (at least in this
system), individual domains could be. This allowed for examina-
tion of the importance of the loop 3–4 (L34) region of human
Rpa2 and Rpa4. It had been demonstrated that the replacement of
the human Rpa2 L34 region with the Rpa4 L34 region resulted in
a human Rpa2 hybrid protein that can no longer support DNA
replication in human tissue culture and in vitro [28,32]. We
demonstrated that the replacement of the yeast Rfa2 predicted
L34 region with either the human Rpa2 L34 or Rpa4 L34 had very
little effect on yeast Rfa2 function in yeast cells. This highlights
two important points. First, the human Rpa4 L34 region does not
inhibit Rfa2 function in DNA replication or repair in yeast cells,
indicating that the negative effect of the Rpa4 L34 region on
cellular replication is speciﬁc to human cells. We propose that the
negative effect observed in human cells is mediated through
human-speciﬁc protein interactions (or lack thereof). Second, the
L34 region of yeast Rfa2 has been previously reported to be
phosphorylated [39–41]. While we cannot rule out the possibility
Fig. 6 – Hybrid Rfa2 containing the human Rpa2 N-terminus
is phosphorylated at the same residues as in human cells.
(A) The hybrid Rfa2-h2NT is phosphorylated on multiple serines/
threonines. To determine if phosphorylation is occurring on
speciﬁc S/T residues, Western blotting with human Rpa2
phospho-speciﬁc antibodies (right-side blots with speciﬁc
antibody used denoted to the right of each blot) was
performed. Blots on left half represent resolution of
approximately equal amounts of total Rfa2 or Rfa2-h2NT
(not total protein). MMS treatment and designations are as in
Fig. 5B. The anti-yeast Rfa2 antibody recognizes all species,
and the phospho-speciﬁc antibodies recognize only the
Rfa2-h2NT species that have been phosphorylated at that
particular residue. The asterisk for the blot detected with
pS12-speciﬁc antibody indicates a non-speciﬁc species.
(B) Comparison of phosphorylation of human Rpa2 in human
cells vs. the human Rfa2 hybrid in yeast cells. Shown are the
ﬁrst 38 amino acid residues of the human Rpa2 N-terminus.
Sites of phosphorylation are shown in larger font and bold.
Human kinases that recognize and phosphorylate each residue
in human cells are designated above the sequence. Only CDK
sites are not strictly damage-speciﬁc in human cells. Denoted
below the sequence are residues identiﬁed to be
phosphorylated on Rfa2-h2NT in yeast cells. The condition
in which phosphorylation is observed is denoted below
the arrows.
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Rpa2 or Rpa4 L34 region is present, we can conclude that the
amino acid sequence in this region appears to be relatively
unimportant. Both of the points above suggest that this loop is
there for structural purposes in yeast and may be important for
additional activities in human cells (and potentially other higher
eukaryotes).The human Rpa2 N-terminus is a target for
phosphorylation by yeast kinases
The domain swap of particular interest was the replacement of
the Rfa2 N-terminus with the human Rpa2 or Rpa4 N-terminus.
Although this domain in yeast Rfa2 is not hyper-phosphorylated
like human Rpa2, it is clearly required for yeast Rfa2 function in
the DNA damage response. Swapping the yeast Rfa2 N-terminus
for either the human Rpa2 or Rpa4 N-terminus revealed a number
of features. Both the human Rpa2 and Rpa4 N-termini support
DNA replication and repair, as both displayed viability and DNA
damage resistance in yeast cells. Also, the human Rpa2 and Rpa4
N-termini are phosphorylated during the cell cycle and in
response to DNA damage in yeast cells; however, the phosphor-
ylation of human Rpa2 is much more pronounced. Also, phos-
phorylation occurs on the same serines/threonines on the hybrid
Rfa2-h2NT in yeast as it does for human Rpa2 in stressed human
cells. This suggests that the difference in phosphorylation of yeast
Rfa2 vs. human Rpa2 (or human Rpa4) is simply sequence—the
serines/threonines in the yeast Rfa2 N-terminus are not sur-
rounded by appropriate residues that allow for recognition by
yeast kinases. However, the observation that yeast kinases recog-
nize and act on the human Rpa2 N-terminus suggests that if
phosphorylation of other eukaryotic Rpa2 N-termini is occurring,
the mechanism of phosphorylation might be conserved.
An interesting difference in human Rpa2 N-terminal phosphor-
ylation in yeast vs. human cells lies in residues that display
damage-speciﬁc phosphorylation. In human cells, phosphoryla-
tion of S4/S8, S12, T21, and S33 is DNA damage-dependent. In
yeast cells, only phosphorylation of S4/S8 and S12 appear to
depend on DNA damage. Recently, it was shown that human cells
in G2 display chromatin-bound Rpa2 that is phosphorylated on
S33 in the absence of DNA damaging agent and is increased upon
damage induction [51]. Yeast cells that are grown exponentially
are predominantly in G2/M phase, and this could explain the
apparent phosphorylation of S33 on Rfa2-h2NT in undamaged
cells. However, there is not an obvious increase in S33 phosphor-
ylation upon DNA damage in yeast cells. The other major
difference lies in modiﬁcation of T21, which in yeast cells appears
to be phosphorylated in both unstressed and stressed cells.
Phosphorylation of T21 is one of the ﬁrst residues to be phos-
phorylated in a damage-speciﬁc manner in human cells [51] and
appears to be important for priming phosphorylation of other
sites [17]. It is possible that low levels of damage that occur
naturally in exponentially growing yeast cells are enough to
trigger phosphorylation of T21 in the absence of damage induc-
tion. However, like phosphorylation of S33, this phosphorylation
is not obviously increased in damaged yeast cells (at least those
treated with MMS). Consistent with human Rpa2 phosphorylation
in human cells, the Rfa2-h2NT hybrid protein is also phosphory-
lated in a damage-speciﬁc manner in yeast.
An alternative explanation for condition-speciﬁc phosphoryla-
tion differences could simply lie in the sequence and the kinase(s)
that recognize it. Fig. 6B shows a summary of the phosphorylation
of the human Rpa2 N-terminus in human and yeast cells. In
human cells, generally ATR/ATM/DNA-PK recognizes S/TQ motifs
(T21 and S33), CDK recognizes the SP motifs (S23 and S29), and
DNA-PK recognizes the other non-consensus sites (S4/S8 and S12)
[17,52,53]. It should be noted that in yeast, S29 is not condition-
speciﬁc, indicating that SP motifs are potentially recognized by
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T21 and S33 are within SQ and TQ motifs that would presumably
be recognized by Mec1/Tel1 (ATR/ATM homologs); however, these
kinases are normally activated by DNA damage. It is possible that
some fraction of Mec1/Tel1 is active in exponentially-growing
cells and phosphorylates the human Rpa2 SQ and TQ sites, similar
to ATR/ATM regulating replication initiation during the cell cycle
in unperturbed human cells [54]. It is also possible that another
kinase(s) is active during the cell cycle in yeast recognizes and
phosphorylates these motifs. Perhaps most interesting is the
observation that serines (S4/S8 and S12) without an SQ motif
displayed damage-speciﬁc phosphorylation in both human and
yeast cells. The lack of an obvious DNA-PK homolog in yeast
makes identiﬁcation of the kinase involved in phosphorylating
S4/S8 and S12 in yeast cells potentially interesting.
Why is hyper-phosphorylation not observed in the
N-terminus of yeast Rfa2?
Yeast Rfa2 requires an intact N-terminus to support its function in
response to DNA damage. This is not only based on the observa-
tion that mutation of this domain to an unphosphorylated form
supports DNA damage resistance, but also on the observation that
substituting the human Rpa2-Ax (h2Ax; cannot be phosphory-
lated) mutant form into yeast Rfa2 also results in damage-
resistant cells. Taken together with the fact that deletion of the
Rfa2 N-terminus results in damage-sensitive cells, this indicates
that this domain needs to be present, but does not need to
be phosphorylated for yeast cells to respond to DNA damage.
This also suggests that a substantially (and/or constitutively)
negatively-charged N-terminal region, while potentially beneﬁcial
in human cells, might be detrimental in yeast cells. This is based
on the observation that yeast Rfa2-y2Dx and hybrid Rfa2-h2Dx
mutant cells display DNA damage-sensitive phenotypes. In both
mutants, the N-terminus is constitutively negatively-charged to
mimic hyper-phosphorylation of this region. We propose that
hyper-phosphorylation of human Rpa2 has potentially co-evolved
with machinery necessary for DNA repair and cell cycle regulation
speciﬁcally found in higher eukaryotes.
One ﬁnal observation is the apparent molecular weight differ-
ences between the WT Rfa2 protein and the hybrid Rfa2-h2NT or
Rfa2-h4NT proteins. Both of the hybrid proteins have an apparent
molecular weight that is smaller by approximately 2–4 kDa,
despite all three proteins being the exact same length in amino
acids. This suggests that the N-terminus of yeast Rfa2 is more
negatively-charged than the human Rpa2 or Rpa4 N-termini,
which does appear to be reﬂected by a cursory examination of
positively- and negatively-charged residues found in these
domains. Perhaps this feature substitutes for an apparent lack of
phosphorylation of this domain in yeast—it is already in the
negatively-charged state necessary to function in yeast cells,
especially in response to DNA damage. Consistent with this is
the qualitative ranking of apparent damage-sensitivities for
mutants (Fig. 4C). The yeast rfa2-Ax (y2Ax) mutant is nearly as
resistant as WT (yeast-derived with same charged residue
makeup as the Rfa2 N-terminus), followed by rfa2-h4L34 and
rfa2-h2L34 (contain the exact same N-terminus as yeast Rfa2),
followed by rfa2-h4NT and rfa2-h2NT (human-derived N-terminus
that is less negative than Rfa2 but post-translationally modiﬁed to
give these proteins an apparent molecular weight nearlyindistinguishable from Rfa2), followed by rfa2-h2Ax (human-
derived and less negatively-charged with no opportunity for
N-terminal phosphorylation), followed by the remainder of
mutants that either have no domain or contain a constitutively
negatively-charged domain.
Implications of hybrid Rfa2 phosphorylation studies
The ﬁrst implication of these studies is that S. cerevisiae provides
the potential for studying the human Rpa2 N-terminus. This is not
to imply that studies in yeast cells will yield insights into human
Rpa2 N-terminus cellular function (although it is possible), as it is
clear that phosphorylation of the yeast Rfa2 N-terminus is not
necessary for cellular resistance to DNA damage in standard assays
commonly used in yeast. Rather, this is to imply that we now have
the opportunity to compare and contrast features of phosphoryla-
tion that occur in human cells. For example, one can address the
following: (1) whether phosphorylation is sequential or primed by
phosphorylation of other sites, (2) what damaging conditions elicit
phosphorylation (initially investigated in this study), (3) what yeast
kinases are involved, and (4) if phosphorylation of the human Rpa2
N-terminus is phase-speciﬁc. Although some the above questions
have been addressed in human tissue culture cells [12,17], exam-
ination in yeast cells might provide insight (and perhaps consen-
sus) into the mechanism by which phosphorylation occurs in
higher eukaryotes. It might also provide insight into how yeast
RFA does similar functions in the absence of obvious hyper-
phosphorylation of the Rfa2 N-terminus and other proteins that
are higher eukaryote-speciﬁc (i.e., DNA-PK).
The second implication is the use of S. cerevisiae as a tool for
understanding the relevance of (hyper-) phosphorylation of Rpa2
subunits from other organisms. It is difﬁcult to study the function
of Rpa2 in the context of the whole organism. This is why yeast or
human tissue culture is so powerful. However, there are many
organisms in which it is not clear if RPA functions in a similar
manner or whether or not it is post-translationally modiﬁed (it is
often just assumed to be similar). As an example, in plants, there
are multiple Rpa2 subunits, which have been proposed to have
potentially different roles [55–57]—post-translational modiﬁca-
tion of these Rpa2 forms has not been addressed. In fact, in most
organisms besides humans, Xenopus, Candida, and now Sacchar-
yomyces [22–24,58–60], Rpa2 NT phosphorylation has not been
examined in detail. Given that the human Rpa2 N-terminus is
phosphorylated in yeast, we propose that this system would
provide a relatively simple tool for addressing whether other
Rpa2 N-termini from other organisms might also be phosphory-
lated. Extending this to organisms with multiple Rpa2 subunits
might provide insight or additional evidence for which Rpa2
subunits might be actively playing a role in the DNA damage
response.Materials and methods
Yeast strains
Yeast strains used in this study are listed in Table S1. For plasmid
shufﬂe (determining viability and recovering rfa2 mutants), the
W303 derivative RMY122-A (rfa1Δ::TRP1 rfa2Δ::TRP1) containing
the plasmid pJM132 (RFA1 RFA2 URA3) [61] was used. In vivo
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strain EGY48 (6xOlexA-LEU2) was used for all two-hybrid analyses
[64, 65].
Plasmid construction
All primers used and plasmids generated are listed in Tables S2
and S3, respectively. To generate a yeast vector containing the
human Rpa1, Rpa2, and Rpa3 genes driven by native RFA1, RFA2,
and RFA3 promoters, PCR and in vivo cloning [62] were utilized.
Brieﬂy, primers containing 40 nucleotides (nt) immediately
upstream of the coding region for each RFA subunit gene and
the initial 20 nt of coding region of the homologous human RPA
subunit gene were designed. Primers were also designed contain-
ing 40 nt immediately downstream of the coding region for each
RFA subunit gene and the last 20 nt of coding region (including
the stop codon) of the homologous RPA subunit gene. Utilizing
plasmid templates containing Rpa1, Rpa2, Rpa4, or Rpa3 full-
length cDNA, Phusion DNA polymerase (New England Biolabs)
was used to generate rfa1Δ::Rpa1, rfa2Δ::Rpa2 (or rfa2Δ::Rpa4),
and rfa3Δ::Rpa3 PCR fragments.
RFA2 was ﬁrst replaced with Rpa2 (or Rpa4) by digesting
pJM132 with HpaI. This linearized vector was co-transformed
with the rfa2Δ::Rpa2 (or rfa2Δ::Rpa4) PCR fragment into EGY40
cells. Transformants were selected on synthetic complete (0.5%
ammonium sulfate, 0.34% yeast nitrogen base without amino
acids) media containing 2% dextrose and lacking uracil (SD-Ura).
Genomic and plasmid DNA were isolated from a scrape of yeast
transformants and electroporated into DH10B bacterial cells.
Bacterial transformants were selected on LB media containing
100 μg/mL ampicillin (LBþAmp). Plasmid DNA was isolated from
independent bacterial colonies, and correct substitution candi-
dates were veriﬁed by restriction digestion and DNA sequencing
(Eton Bioscience). The resulting veriﬁed vectors were called
pPLG35 and pPLG36.
Once veriﬁed, the RFA3 gene was replaced with Rpa3 by
digesting pPLG35 (or pPLG36) vectors with AatII and co-
transforming them into EGY40 cells along with the rfa3Δ::Rpa3
PCR fragment. The same procedure as above was followed, and
candidates were veriﬁed by DNA sequencing. The resulting
veriﬁed vectors were designated pPLG37 and pPLG38. Next, the
RFA1 gene in these plasmids was replaced with Rpa1 by digesting
pPLG37 (or pPLG38) vectors with AatII and co-transforming with
the rfa1Δ::Rpa1 PCR fragment into EGY40 cells. Following the
same procedure as previously, candidates were isolated and
veriﬁed by sequencing. These resulting plasmids are pPLG39
and pPLG40, respectively. Following a similar procedure, the
URA3 gene of pPLG39 and pPLG40 was deleted and replaced with
a kanMX cassette (ura3Δ::kanMX) to generate pPLG41 and
pPLG42, respectively. kanMX insertion was veriﬁed by restriction
digest.
To generate chimeric RFA2 genes encoding for yeast Rfa2 with
the human Rpa2 N-terminus (NT), human Rpa4 NT, or corre-
sponding human Rpa2 NT phospho-mutants, in vivo homologous
recombination cloning was utilized. Double-stranded DNA frag-
ments encoding for the human Rpa2 NT (h2NT), human Rpa4 NT
(h4NT), or the Rpa2 NT phospho-mutant forms, Rpa2-Dx (h2Dx),
Rpa2-Ax (h2Ax), or Rpa2-ΔNx (h2ΔNx), were generated as double-
stranded gBlock fragments (Integrated DNA Technologies). The
gBlock fragments also contained sequence upstream anddownstream that encoded for the yeast RFA2 endogenous pro-
moter and the remainder of the RFA2 coding region starting at
amino acid 39, respectively (Table S4). These fragments were
combined with NcoI-digested pAW10 and transformed into the
yeast strain EGY40. Leucine prototrophs were selected, and
genomic/plasmid DNA was isolated. This DNA was electroporated
into DH10B bacterial cells, and plasmid DNA was isolated from
ampicillin-resistant transformants. To verify incorporation of the
human Rpa2 NT forms into the N-terminus of the yeast RFA2
gene, the resulting plasmid DNA was digested and veriﬁed by
DNA sequencing (Eton Bioscience).
Yeast/human chimeric genes encoding RFA2, where the Rfa2
loop 3–4 region was substituted with the acidic loop 3–4 region of
human Rpa2 (Rpa2-L34) or the basic loop 3–4 region of Rpa4
(Rpa4-L34), were also generated via in vivo homologous recom-
bination cloning (rfa2-h2L34 and rfa2-h4L34, respectively). gBlock
fragments were generated in a similar fashion as above, except
that the loop 3–4 region encoding amino acid (aa) residues 102–
132 of Rfa2 was substituted with the region encoding aa 108–124
of human Rpa2 or aa 108–123 of human Rpa4. These fragments
were combined with SnaBI-digested pAW07 and transformed into
EGY40 yeast cells. After isolation of DNA as described above, the
resulting plasmid DNA were identiﬁed by double-digestion with
NcoI-SnaBI and veriﬁed by DNA sequencing.
Human RPA and yeast RFA subunit-expressing bait (pENM5)
and prey (pENM10, pENM11, pENM12, pENM13, pENM14,
pENM15, and pENM16) constructs for two-hybrid analysis were
generated as follows. PCR using the appropriate subunit template
DNA and Phusion DNA polymerase was performed with sets of
primers listed in Table S2. Brieﬂy, RFA1, RFA2, RFA3, Rpa1, Rpa2,
Rpa3, and Rpa4 were ampliﬁed by PCR using primers with 40 nt
(on the 50 end) of homologous sequence to the appropriate
cloning vector and 20 nt (on the 30 end) of complementary
sequence to the desired yeast RFA or human RPA subunit gene.
pEG202K or pJG4-5 were digested with NcoI or EcoRI, respectively,
to linearize each fragment. The linearized vectors were co-
transformed with the corresponding PCR-ampliﬁed RFA subunit
gene into EGY48, and transformed cells were plated onto media
lacking histidine (SD-His) or lacking tryptophan (SD-Trp) for cells
transformed with pEG202 or pJG4-5, respectively. The resulting
colonies, some containing recombined vectors, were then scraped
from the plates, DNA (both genomic and plasmid) was isolated
and electroporated into DH10B bacterial cells. The bacterial cells
containing plasmids were selected for on LB plate media contain-
ing 100 μg/mL ampicillin (LBþAmp). Plasmid DNA was isolated
from individual bacterial colonies and analyzed by diagnostic
restriction digests. Plasmids with inserts were sequenced (Eton
Bioscience).
Yeast two-hybrid assay
Protein interactions between yeast RFA and human RPA subunits
were examined using the DupLEX-A Yeast Two-Hybrid System
(Origene). Bait (lexA BD) constructs (described in [33, 66]) were
each co-transformed into EGY48 (leu2::6xOlexA-LEU2) with prey
(B42 AD) constructs containing each of the individual RFA or RPA
subunits and the reporter construct pSH18–34 (8xOlexA-lacZ).
Transformants were selected on synthetic complete media con-
taining dextrose (2%) and lacking histidine, tryptophan, and uracil
(SD-HTU). Independent colonies were patched to SD-HTU and
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lacking histidine, tryptophan, uracil, and leucine (SD-HTUL),
synthetic galactose (2%) media lacking histidine, tryptophan,
uracil, and leucine (SG-HTUL), and synthetic galactose media
lacking histidine, tryptophan, and uracil containing 40 μg/mL
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (SG-HTUþX-gal).
Plates were grown for 2–4 days at 30 1C.Assessing viability and isolation of yeast cells expressing
Rfa2:Rpa2/4 hybrid proteins via plasmid shufﬂe
To examine the viability of yeast cells containing human RPA (all
three subunits), the strain RMY122-A containing a deletion of
both the rfa1 and rfa2 endogenous genes and a plasmid (pJM132)
with the wild-type (WT) forms of RFA1 and RFA2 driven by their
native promoters was transformed with pPLG41 (rfa1Δ::Rpa1
rfa2Δ::Rpa2 rfa3Δ::Rpa3) or pPLG42 (rfa1Δ::Rpa1 rfa2Δ::Rpa4
rfa3Δ::Rpa3). Transformants were selected on YPD (1% yeast
extract, 2% peptone, and 2% dextrose) containing 200 μg/mL
G418 sulfate (YPDþG418). Control cells were transformed with
pRS313-RFA1 and pAW07 containing WT RFA1 and RFA2, respec-
tively, and transformants were selected for using synthetic
dextrose (2%) media lacking histidine, leucine, and uracil (SD-
HLU). Transformed (control and experimental) cells were grown
in liquid YPD or YPDþG418, respectively, at 30 1C overnight. The
next day, the cells were sonicated (Branson Soniﬁer 450) using a
microtip and pulsed at 20% for 1 s (0.2 s on/0.5 s off). Cells were
then quantitated on a cell counter (Nexcelom), and diluted in 1
PBS to 1107 cells/mL. Ten-fold serial dilutions were made in 1
PBS and 5 μL cells of each dilution were spotted onto YPDþG418,
SD-HLU, synthetic dextrose media containing 0.8 μg/mL 5-
ﬂuororotic acid (5-FOA), and YPG (1% yeast extract, 2% peptone,
2% glycerol) plates and incubated at 30 1C for 3–5 days. Viability
was assessed qualitatively based on the ability of cells to lose
pJM132 and grow on 5-FOA-containing media.
Plasmid shufﬂe was also utilized to generate yeast cells
expressing a chimeric RFA2-Rpa2/4 gene as the only form in the
cell. The strain RMY122-A was transformed with pRS313-RFA1
and pAW07 (or a derivative plasmid expressing a chimeric RFA2
gene). Yeast cells containing all three plasmids were selected for
and grown overnight at 30 1C in SD-HLU. Cells were treated and
spotted as described above. To recover individual shufﬂe-out cells,
5104 cells were spread onto 5-FOA plates.DNA damage assays of Rfa2:Rpa2/4 hybrid protein-
expressing yeast cells
Once isolated, RFA2-Rpa2/4 hybrid protein-expressing yeast cells
were grown overnight in YPD at 30 1C with shaking. Again, cells
were sonicated and counted as described above. The cells were
then diluted to 2.5105 cells/mL, and three-fold dilutions were
made in 1 PBS. The dilutions were then spotted to the following
plates: YPD containing 0.0019–0.015% methyl methanesulfonate
(MMS), YPD containing 0.2–25 μg/mL camptothecin (CPT), YPD
containing 40–320 mM hydroxyurea (HU), YPD containing 0.2–
25 μg/mL phleomycin (PHL), YPD, SD-HLU, and YPG plates. All of
the plates were incubated at 30 1C. The duration of incubation was
between 2 and 5 days, depending on the media used.Quantitative real-time PCR to examine RPA or RFA subunit
gene expression
RMY122-A cells containing no additional plasmid, pPLG41 (cano-
nical RPA-expressing), or pPLG42 (alternative RPA-expressing)
were grown overnight in YPD. RNA was isolated from these cells
using the YeaStar RNA Kit (Zymo Research). Genomic DNA was
removed from the samples using the DNA-Free RNA Kit (Zymo
Research), and the RNA was quantitated using a Nano-Drop
(Thermo). cDNA was then generated using the AMV First Strand
cDNA Synthesis Kit (New England BioLabs). Primer sets were
designed for the human RPA or yeast RFA subunit genes using
Primer Express (Applied Biosystems) or PrimerQuest (Integrated
DNA Technologies), respectively. Primers were also designed for
the normalizing control yeast gene UBC6. All primers are listed in
Table S2. cDNA was then ampliﬁed using PerfeCTa SYBR Green
FastMix Low ROX (Quanta Biosciences) and performed on an
AB7500 Real-Time PCR System (Applied Biosystems). Results were
analyzed using Sequence Detection System (SDS) Software v1.2
(Applied Biosystems).Protein extraction and Western blotting of Rfa2:Rpa2/4
hybrid proteins
To demonstrate that the RFA2-Rpa2/4 hybrid proteins are
expressed, stable, and can be post-translationally modiﬁed fol-
lowing DNA damage treatment, RMY122-A cells containing the
hybrid forms as the exclusive forms of the 32 kDa subunit of yeast
RFA were grown in YPD at 30 1C overnight to exponential phase.
Cells were then diluted to 2.5106 cells/mL and grown for an
additional 4 h. Finally, cells were treated with listed concentration
of damaging agent for 3–5 h. After this incubation, both treated
and untreated cells were isolated and protein was extracted using
a sample buffer lysis method [63]. Protein from 5106 cells
was separated on a 12%, 8%, or 6% SDS-PAGE gel (37.5:1 acryla-
mide:bis-acrylamide). Where noted, protein was quantitated
using the RC-DC Assay Kit (Bio-Rad), and 30 μg/lane was loaded.
After transfer to nitrocellulose, Rfa2 or Rfa2:Rpa2/4 hybrid
proteins were detected using a 1:20,000 dilution of rabbit
polyclonal anti-Rfa2 antibody (kindly provided by Steve Brill),
followed by a 1:40,000 dilution of goat anti-rabbit HRP antibody
(ab97051; Abcam). To detect human speciﬁc phosphorylation, the
following phospho-speciﬁc antibodies and dilutions were used:
rabbit anti-Rpa2 pS4/S8 antibody (A300–245A; Bethyl Labora-
tories) at a 1:2000 dilution, rabbit anti-Rpa2 pS12 (Oakley lab) at
a 1:3000 dilution, rabbit anti-Rpa2 pT21 (ab61065; Abcam) at a
1:1000 dilution, rabbit anti-Rpa2 pS33 (A300–246A; Bethyl
Laboratories) at a 1:2500 dilution, and rabbit anti-Rpa2 pS29
(Borowiec lab) at a 1:3000 dilution. Activation (phosphorylation)
of Rad53 was detected using rabbit anti-Rad53 (ab104232;
Abcam) at a 1:8000 dilution. Yeast Rfa1 and Rfa2 expression
was detected using a 1:40,000 dilution of rabbit polyclonal
antibody to yeast Rfa1 or a 1:20,000 dilution of rabbit polyclonal
antibody to yeast Rfa2 (both kindly provided by Steve Brill).
Human Rpa1 and Rpa2 proteins were detected using a 1:1000
dilution of mouse monoclonal antibody to human Rpa1
(ab176467; Abcam) or a 1:5000 dilution of rabbit polyclonal
antibody to human Rpa2 (kindly provided by Marc Wold).
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